MedRhythms, established in 2015, is a pioneering neurotherapeutics company transforming the treatment of walking impairments from neurologic diseases. Their innovative platform integrates sensors, software, and music to deliver Rhythmic Auditory Stimulation (RAS), enhancing motor function by synchronizing brain regions. The flagship product, “InTandem,” is a digital therapeutic for at-home music therapy aimed at improving walking abilities in chronic stroke patients. Cleared by the FDA in July 2023 and reimbursed through durable medical equipment insurance codes, InTandem exemplifies MedRhythms’ cutting-edge approach. With investment from Universal Music Group in its Series B2 round, MedRhythms leads in applying music to disease treatment.